Skip to main content

Diabetes

  • Diamyd Medical to divide business

    STOCKHOLM Diamyd Medical will split its business into separate divisions for pain relief and diabetes, the drug maker said Friday.

     

    The Swedish company said its diabetes business would consist mostly of the investigational antigen-based drug Diamyd, for Type 1 diabetes, while the pain business would comprise of development projects using its nerve-targeting drug delivery system platform to administer drugs directly to the nervous system to treat pain.

     

     

  • Novo Nordisk looks at ways to raise diabetes awareness in new report

    PRINCETON, N.J. Novo Nordisk is underscoring the importance of diabetes screenings with a new report, the Novo Nordisk BlueSheet.

    The third edition of the drug maker's BlueSheet report examined various ways awareness and education play an integral role in the prevention, detection and treatment of diabetes. It also provides an update on the Diabetes Advocacy Alliance, a coalition that is committed to helping improve diabetes prevention, detection and care by aligning key diabetes stakeholders around diabetes-related policy and legislative efforts.

  • CRC risk may be highest among men with Type 2 diabetes, study finds

    NEW YORK There may be a link between Type 2 diabetes and colorectal cancer among men, according to a new study published in Gastroenterology.

  • American Diabetes Association continues to raise awareness as celebratory month nears

    ALEXANDRIA, Va. American Diabetes Month will be celebrated this November, and the group leading the fight to end the disease is encouraging others to join the movement.

     

    Shortly after announcing that "Celebrity Apprentice" winner and Poison frontman Bret Michaels joined its "Stop Diabetes" movement, the American Diabetes Association has launched the "Share Your Vision to Stop Diabetes" video contest, and has asked Americans to:

  • Pfizer inks deal with Biocon

    NEW YORK Pfizer has entered the world of biosimilars through a deal with India-based Biocon to distribute versions of insulin and insulin analog products around the world, the companies said Monday.

     

  • Diabetes-related hospitalizations on the rise, study finds

    NEW YORK More young adults, particularly young women, are being hospitalized for diabetes-related issues, according to a new study.

    The study — published online in the Oct. 12 edition of Journal of Women's Health, led by Joyce Lee of the University of Michigan in Ann Arbor and colleagues — evaluated hospital discharges with a primary or secondary diagnosis of diabetes from the Nationwide Inpatient Sample between 1993 and 2006.

  • Anthem Blue Cross recognized for its diabetes pilot program

    WOODLAND HILLS, Calif. A local Blue Cross chapter has gained national recognition for its pilot diabetes program.

    Anthem Blue Cross' health equities pilot is 1-of-7 programs recognized this year with a Best of Blue Clinical Distinction Award, an award developed by the Blue Cross Blue Shield Association and the Harvard Medical School department of healthcare policy, Anthem Blue Cross said.

X
This ad will auto-close in 10 seconds